https://en.bioecon.ru/companies/edigene/Recent content in Edigene on BioeconHugoen-USSat, 11 Jul 2026 14:19:14 +0700https://en.bioecon.ru/technology/prime-editing/Fri, 26 Jun 2026 00:00:00 +0000https://en.bioecon.ru/technology/prime-editing/Search-and-replace genome editing with a Cas9 nickase fused to a reverse transcriptase and an extended pegRNA — writing all 12 base substitutions and small indels without a double-strand break.https://en.bioecon.ru/technology/genome-editing/Wed, 24 Jun 2026 00:00:00 +0000https://en.bioecon.ru/technology/genome-editing/Programmable genome editors — CRISPR-Cas9, base editors and prime editors — delivered ex vivo or in vivo via lipid nanoparticles to treat genetic disease, from the first approved CRISPR therapy Casgevy to in-vivo redosable CRISPR and single-dose cardiovascular base editing.https://en.bioecon.ru/technology/base-editing/Fri, 19 Jun 2026 00:00:00 +0000https://en.bioecon.ru/technology/base-editing/Base editors (CBE/ABE) make single-nucleotide changes C·G→T·A and A·T→G·C without double-strand breaks — treating monogenic disease (sickle cell, beta-thalassemia) at up to 90% efficiency with no indels.https://en.bioecon.ru/technology/personalized-regenerative-medicine/Fri, 19 Jun 2026 00:00:00 +0000https://en.bioecon.ru/technology/personalized-regenerative-medicine/Gene and cell therapy platforms for rare monogenic and oncological diseases: AAV vectors, lentiviral HSC editing, ex vivo CRISPR (Casgevy) and in vivo CRISPR (LNP delivery) now deliver durable one-time treatments approved by FDA and EMA.